IntelGenx Technologies Corp. Engages Consulting for Strategic Growth 1 for Investor and Public Relations

July 12, 2007
IntelGenx Technologies Corp. (OTCBB: IGXT) today announced that it has engaged New York-based Consulting For Strategic Growth 1 (CFSG1) to provide strategic counsel on investor and public relations. CFSG1 specializes in introducing promising domestic and international companies to American financial markets.

IntelGenx develops drug delivery technologies for the international pharmaceutical market, to improve existing drug compounds with proven efficacy and safety. Its proprietary controlled release technologies address multiple markets including osteoarthritis, hypertension, pain management and smoking cessation. The Company works with U.S. and European pharmaceutical companies to apply its proprietary drug delivery technologies to high potential drug candidates and will be pursuing a 505(b)(2) application for regulatory approval. This would entitle IntelGenx to three to five years of market exclusivity. Currently the Company has partnership agreements in place for six of its products and plans to develop the balance of its pipeline independently.

Horst G. Zerbe, President and CEO, IntelGenx, commented, "We have created unique drug delivery platforms and a strong product pipeline addressing major markets. We are very pleased to engage CFSG1 to introduce the Company to the investment and financial communities. CFSG1 is highly regarded for its expertise in capital formation and its broad network of public and private investors. We're delighted to have their professional guidance and outreach."

Stanley Wunderlich, CEO, CFSG1, stated, "IntelGenx is an exciting company with unique, proprietary drug delivery technologies and a broad product pipeline addressing multi-billion-dollar markets. We look forward to helping it fulfil its potential."

About IntelGenx Technologies

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral carity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of osteoarthritic, pain management, hypertension and smoking cessaion. Since January 2007, IntelGenx has been trading on the OTCBB.

To learn more about IntelGenx, please visit the Company's website at

About Consulting for Strategic Growth 1, Ltd.

CFSG1 has decades of hands-on corporate development experience combined with broad personal outreach in the private equity markets and Wall Street broker/dealer communities. CFSG1 is a leader in reverse mergers, investor and public relations and corporate development for small-cap companies and private enterprises, both domestic and international. Its portfolio includes businesses based in countries such as China, South Africa and Canada. CFSG1's strategic relationships include Rodman & Renshaw, Inc., a full-range investment bank nurturing emerging growth companies since 1951; Brookshire Securities, a leading Florida investment firm focused on the needs of small to medium sized companies; and, Inc. (CWN), a worldwide financial platform catering to small- and mid-size Chinese companies and the Chinese investor community (, among others. For more information, go to:

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Pursuant to a June 1, 2007 contract, Consulting For Strategic Growth1, Ltd. ("CFSG1") provides IntelGenx Corp. ("the Company") with consulting, business advisory, investor relations, public relations and corporate development services. Independent of CFSG1's receipt of cash compensation from the Company, CFSG1 may choose to purchase the Company's common stock and thereafter liquidate those securities at any time it deems appropriate to do so.

IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
(514) 331-7440 ext. 201
(514) 331-0436 (FAX)

Investor Relations:
Consulting for Strategic Growth 1
Stanley Wunderlich, CEO
(212) 337-8089 (FAX)

Media Relations:
Consulting for Strategic Growth 1
Daniel Stepanek
(212) 896-1202
(212) 697-0910 (FAX)

Source: Market Wire (July 12, 2007 - 7:31 AM EST)

News by QuoteMedia